临床急需与罕见病药品进口便利化高级别对话活动在京举办

Core Viewpoint - The event "Multinational Pharmaceutical Enterprises Shunyi Action" aims to optimize the import pathways for urgently needed and rare disease drugs, enhancing drug accessibility and improving public welfare through collaborative discussions among government departments, medical institutions, and multinational pharmaceutical companies [1][3]. Group 1: Event Overview - The event gathered over 200 participants, including representatives from government agencies, medical institutions, and more than 50 multinational pharmaceutical companies, to discuss key issues related to drug imports and medical trade facilitation [3][5]. - Key topics included the import of urgently needed and rare disease drugs, innovative measures for medical trade ports, and policies empowering the pharmaceutical and health industry [3][5]. Group 2: Policy Insights and Implementation - Authorities from the Beijing Municipal Drug Administration, Health Commission, and other organizations shared insights on drug importation processes, expert evaluations, and pharmaceutical service models to enhance drug accessibility and affordability [4]. - The Shunyi District has introduced supportive policies for the pharmaceutical and health industry, showcasing Beijing's efforts in accelerating market access and creating a favorable business environment [4][7]. Group 3: Economic Impact and Future Prospects - The Shunyi District aims to develop the pharmaceutical health industry as a key sector, with an expected industry scale of 69.1 billion by 2025, achieving an average annual growth rate of 17.4% over three years [6]. - The Tianzhu Comprehensive Bonded Zone has seen its pharmaceutical trade exceed 100 billion for three consecutive years, accounting for nearly one-third of the national total, solidifying its position as the largest pharmaceutical trade port in China [6].